Echo IQ Limited Overview
Echo IQ Limited is an ASX-listed artificial intelligence and medical technology company. It applies machine learning to routinely acquired echocardiography measurements to help cardiologists detect structural heart disease and heart failure. The company describes itself as using "AI-driven technology and proprietary software to improve decision making in cardiology."
Its flagship product, EchoSolv AS, received US FDA 510(k) clearance for detecting severe aortic stenosis in late 2024. It is deployed at Beth Israel Deaconess Medical Center and the Mount Sinai Health System. Its second product, EchoSolv HF for heart failure, received an FDA "Not Substantially Equivalent" determination in September 2026. The company is pursuing an appeal, an Ombudsman review or a resubmission.
Echo IQ is pre-revenue in practice: FY2026 revenue was A$91.6k against a net loss of A$18.6m. However, it is well funded after a A$110m placement in July 2026. It is building a US land-and-expand commercial model through direct sales and partners such as Pro Medicus, the Mayo Clinic Platform, ScImage and SARC MedIQ.
Company's own description (FY2026 Annual Report, paraphrased)
The FY2026 Annual Report describes Echo IQ as an AI and medical technology company focused on improving decision making in cardiology. Its proprietary EchoSolv platform applies AI and machine learning to routinely acquired echocardiographic data. The goal is to help clinicians identify and assess structural heart disease and other cardiovascular conditions.
The directors' report defines the group's principal activity as the development and application of AI for the cardiac diagnostics sector. The FY2026 segment note widens the development scope beyond aortic stenosis. It now includes heart failure, pulmonary hypertension, hypertrophic cardiomyopathy, mitral regurgitation and cardio-oncology.
Independent characterisation
Echo IQ is best understood as an early-commercial, venture-stage clinical decision support software company. Its technology does not interpret echo images directly. Instead, it ingests the structured measurement set already recorded in a standard echocardiography report (more than 140 measurements, according to Stockhead's description of EchoSolv HF). It then produces a disease-likelihood score.
This design has three consequences:
Integration is light: The software sits downstream of existing echo reporting systems and PACS (picture archiving) workflows.
Training data is scalable: The core asset is exclusive access to the National Echo Database of Australia (NEDA), which links echo measurements to patient outcomes. It is now supplemented by up to one million studies licensed from Advara HeartCare.
Regulatory exposure is concentrated: Each new indication needs its own FDA clearance. The September 2026 heart-failure determination shows that regulatory risk falls on the predicate-device argument, not just on clinical performance.
Business model and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Product vs service mix | Software as a medical device (SaMD), licensed per scan or by enterprise contract | FY2025 AR: SARC MedIQ pays per scan; Miscellaneous Code 93799 is used fee-per-use |
| Subscription / licensing | Emerging enterprise contracts (VIEW and SHADOW evaluation programs leading to full deployment) | FY2026 AR: three enterprise proposals covering 300+ hospitals |
| Reimbursement-linked revenue | US$100–150 per use under Miscellaneous Code 93799, with Echo IQ receiving 30–60% of total reimbursement | FY2025 AR |
| Data and research revenue | Funded pilots and trials, such as an Australia/New Zealand structural-heart device company pilot and the Edwards Lifesciences-funded aortic stenosis trial in 2021 | FY2025 AR; Stockhead 2021 |
| Revenue recognised | A$91.6k in FY2026, all from Australia except A$1k from the US. Customer cash receipts were nil. | FY2026 AR, Note 4 and segment note |
Value chain position
Echo IQ sits at the clinical-interpretation layer of the cardiac imaging chain:
-
Echo acquisition, using hardware from GE HealthCare, Philips, Siemens Healthineers and others.
-
Measurement and reporting, using cardiology PACS and structured reporting from vendors such as ScImage, SARC MedIQ and Pro Medicus Visage 7 Cardiology.
-
EchoSolv AI decision support, which flags at-risk patients.
-
Referral to treatment, such as transcatheter aortic valve replacement or heart-failure therapy.
The downstream link matters. Diagnosing more severe aortic stenosis drives valve-replacement procedures (around US$22,000–28,000 each in the US, per Biotech Daily, November 2024). This is why valve makers such as Edwards Lifesciences have funded the company's evidence generation.
Customer types and end-markets
Hospital systems and academic medical centres (primary): Beth Israel Deaconess Medical Center (Boston) and Mount Sinai Health System (New York). The pipeline exceeds 70 hospitals.
Imaging and PACS channel partners: ScImage/MedAxiom, SARC MedIQ, Pro Medicus (proposed reseller) and the Mayo Clinic Platform Solutions Studio (contingent on heart-failure clearance).
Medical device and pharmaceutical companies: used for patient-finding programs, such as the Australia/New Zealand quality-assurance pilot with an unnamed global structural-heart company.
End-markets: US cardiology (aortic stenosis and heart failure). Australia and New Zealand are pilot markets. Europe, the UK and Australia are flagged as future regulatory pathways in the FY2026 outlook.
Financial Narrative
Basis. Audited figures from the FY2023–FY2026 reports. FY2022 revenue and net loss come from the five-year table in the FY2025/FY2026 remuneration reports. FY2024 figures follow the FY2025 Annual Report restatement where it differs from the unaudited FY2024 Appendix 4E (differences are noted). FY2026 is reported in A$ thousands.
Income statement
Calculation notes:
Gross profit: no cost-of-sales line is disclosed.
EBITDA: pre-tax loss plus D&A. It includes interest income because the company has no finance costs.
FY2023 EPS: total figure (continuing −1.84c; discontinued +0.09c).
Pre-FY2022: FY2021 revenue was A$983.2k and the net loss A$2.99m (FY2025 AR five-year table).
Margins
Revenue CAGR FY2022–FY2026: −43.6% per year (analyst calculation, (91.6/904.1)^(1/4) − 1). This figure is distorted by the exit from the legacy Houston We Have software business. On a like-for-like cardiac-AI basis, revenue has fluctuated between A$45k and A$107k with no compounding trend.
Commentary. Margins are not a useful performance measure here. The figures that matter are:
Cash operating expenses: rose 57% in FY2026 to A$13.75m, led by employee costs (+89%), consulting and professional fees (+42%) and marketing (+186%).
Share-based payments: stayed around A$6.2m for the second year running, about one-third of the reported loss.
Grant income: fell from A$1.95m (FY2024) to A$0.76m (FY2026), so there is less non-dilutive funding to offset spending.
The inflection point is FY2025–FY2026. The company moved from a sub-A$7m cash opex base to a US commercial build, and the loss widened 40% in FY2026 even as utilisation grew.
Balance sheet
FY2022 cash, equity, contributed equity and accumulated losses are the opening balances at 1 July 2022 in the FY2023 statements.
Post-balance-date pro forma (analyst view). The A$110m placement settled on 6–7 July 2026. The company stated cash at bank exceeded A$105m as of July 2026 (Smallcaps, citing the September 2026 announcement). The Pro Medicus convertible notes (A$10m initial) were documented on 17 August 2026. The FY2026 AR states funding remained subject to conditions, including a binding reseller agreement. Whether the notes have been drawn is not publicly confirmed in the documents reviewed. If drawn, gross debt would be A$10m, offset by the equivalent cash.
Cash flow
FY2024 operating cash flow and financing follow the FY2025 AR comparatives (−A$3.924m and A$2.765m). The unaudited FY2024 4E reported −A$4.015m and A$2.855m.
Cash-flow commentary. Customer receipts were nil in FY2026. The A$91.6k of revenue recognised came from releasing a A$100k contract liability (customer prepayment) carried at 30 June 2025, and Börse Express reported no customer revenue for FY2026. Operating cash burn rose 62% to A$10.6m. Quarterly data show acceleration: A$2.51m in the September 2025 quarter and A$5.18m in the December 2025 half.
At a run rate of roughly A$14–20m in FY2027 (analyst assumption, given a ~25% salary uplift and continued US hiring), July 2026 cash of more than A$105m implies a runway well beyond five years before acquisitions. The constraint on the business is commercial traction, not funding.
Ratios
Notes: ROIC is not meaningful (negative operating returns; invested capital is mostly cash and the NEDA intangible). Net debt/EBITDA is not meaningful because of net cash and negative EBITDA. Interest coverage is not meaningful because there is no interest expense. The cash conversion cycle is not meaningful given near-zero revenue and no inventory.
Ratio commentary. Negative ROE above 100% in FY2026 reflects a loss that exceeds the year-end equity base, which had been depleted before the July 2026 raise. Pro forma equity after the raise is roughly A$120m. On that basis, an FY2027 loss of A$20–25m would imply ROE of about −20%.
The current ratio swings with the timing of raises. The balance sheet is debt-free with no covenants, although Note 16 contains generic covenant language. The going-concern material uncertainty flagged at FY2024 has been removed: FY2025 and FY2026 opinions are unmodified.
Half-year and quarterly operating metrics
There is a discrepancy on June-quarter growth. The FY2026 AR cites about 11% quarter-on-quarter growth in echos processed, while Börse Express reported 20%. The raw figures (9,220 to about 10,200) imply about 11%.
7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING
Segment-by-geography matrix (FY2026)
Country-level detail beyond the US and Australia is not disclosed. New Zealand pilot activity (part of the Australia/New Zealand structural-heart pilot) and the UK references in third-party profiles are not separately reported.
Fastest-growing and declining regions
Fastest growing (by activity, not revenue): United States: Utilisation is the leading indicator. EchoSolv AS echo volumes grew about 131% quarter-on-quarter in the March 2026 quarter and more than 400% year-on-year in the June 2026 quarter. The US pipeline grew to 70+ hospitals. US revenue has not followed because:
-
The Category III CPT code was rejected in October 2025.
-
Miscellaneous Code 93799 reimbursement is discretionary and slow to collect.
-
Early deployments (VIEW, SHADOW, BIDMC research) are evaluation or research-oriented.
Declining: Australia: Revenue fell 10% in FY2026. Australian revenue is project-based (pilots and trials) and is not expected to scale. Australia is effectively the research and development base and NEDA data centre, not a commercial market.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 904.1 | 107.3 | 44.5 | 101.4 | 91.6 |
Revenue growth YoY (%) | — | -88.1 | -58.5 | 127.9 | -9.6 |
Other income incl grants and interest (AUD K) | — | 73.8 | 1,996.9 | 1,578.9 | 1,282 |
Government grants / R&D incentive (AUD K) | — | — | 1,949.6 | 1,260.9 | 763 |
Interest income (AUD K) | — | — | 47.3 | 201.9 | 519 |
Total operating expenses incl SBP (AUD K) | — | 8,447.0 | 7,450.6 | 14,942.8 | 19,940 |
Operating expenses excl SBP (AUD K) | — | 6,066.6 | 6,642.3 | 8,746.1 | 13,750 |
Share-based payments expense (AUD K) | — | 2,380.3 | 808.3 | 6,196.7 | 6,189 |
Depreciation and amortisation (AUD K) | — | 607.3 | 603.7 | 577.2 | 549 |
Operating income / EBIT, continuing (AUD K) | — | -8,265.8 | -5,409.1 | -13,262.5 | -18,566 |
EBITDA (AUD K, analyst calc) | — | -7,658.5 | -4,805.5 | -12,685.3 | -18,017 |
Pre-tax income, continuing (AUD K) | — | -8,265.8 | -5,409.1 | -13,262.5 | -18,566 |
Profit from discontinued operations (AUD K) | — | 410.2 | 0 | 0 | 0 |
Net income (AUD K) | -5,992.0 | -7,855.6 | -5,409.1 | -13,262.5 | -18,566 |
EPS basic (A cents) | — | -1.75 | -1.09 | -2.26 | -2.84 |
EPS diluted (A cents) | — | -1.75 | -1.09 | -2.26 | -2.84 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (millions) | — | — | 497.6 | 585.7 | 652.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating margin (%) | — | -7,701 | -12,155 | -13,079 | -20,258 |
EBITDA margin (%) | — | -7,137 | -10,799 | -12,510 | -19,659 |
Net margin (%) | -663 | -7,319 | -12,155 | -13,079 | -20,258 |
SBP as % of total operating expenses | — | 28.2 | 10.8 | 41.5 | 31.0 |
Expense line (AUD K)
| Expense line (AUD K) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Employee costs (AUD K) | 2,586.1 | 2,924.3 | 3,239.8 | 6,113 |
Consulting and professional fees (AUD K) | 1,543.2 | 1,657.5 | 2,498.5 | 3,549 |
Directors fees (AUD K) | 376.7 | 494.9 | 820.5 | 635 |
Marketing and PR (AUD K) | 105.1 | 12.8 | 266.7 | 763 |
Other expenses (AUD K) | 664.8 | 804.8 | 1,133.7 | 1,934 |
Audit fees (AUD K) | 75.8 | 69.3 | 76.1 | 80 |
Share registry and listing (AUD K) | 107.7 | 75.1 | 133.6 | 128 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | 2,406.9 | 3,276.4 | 2,117.3 | 6,617.7 | 8,712 |
Term deposits (AUD K) | 0 | 0 | 0 | 11,518.3 | 0 |
Total liquidity: cash plus deposits (AUD K) | 2,406.9 | 3,276.4 | 2,117.3 | 18,136.0 | 8,712 |
Total current assets (AUD K) | — | 3,978.0 | 2,453.5 | 18,645.6 | 9,644 |
Intangible assets incl NEDA (AUD K) | — | 6,367.0 | 5,783.1 | 4,686.9 | 4,162 |
Goodwill (AUD K) | — | 0 | 0 | 0 | 0 |
Total assets (AUD K) | — | 10,383.7 | 8,255.6 | 23,372.3 | 13,875 |
Total current liabilities (AUD K) | — | 3,000.9 | 1,487.6 | 615.4 | 2,246 |
Short-term debt (AUD K) | — | 0 | 0 | 0 | 0 |
Long-term debt (AUD K) | — | 0 | 0 | 0 | 0 |
Net debt, negative = net cash (AUD K) | -2,406.9 | -3,276.4 | -2,117.3 | -18,136.0 | -8,712 |
Total equity (AUD K) | 8,020.0 | 7,382.8 | 6,768.0 | 22,756.9 | 11,629 |
Contributed equity (AUD K) | 30,400.3 | 35,997.4 | 41,530.2 | 64,618.5 | 68,153 |
Accumulated losses (AUD K) | -27,715.3 | -35,191.7 | -39,095.3 | -49,031.6 | -65,524 |
Working capital (AUD K) | — | 977.1 | 965.9 | 18,030.1 | 7,398 |
Shares on issue at year end (millions) | — | 472.3 | 537.7 | 645.2 | 660.9 |
NTA per share (A cents) | — | 0.23 | 0.18 | 2.80 | 1.13 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD K) | — | 107.9 | 37.5 | 200.0 | 0 |
Operating cash flow (AUD K) | — | -4,940.3 | -3,924.2 | -6,508.9 | -10,564 |
Capex incl intangibles (AUD K) | — | -339.7 | 0 | -35.8 | -53 |
Free cash flow (AUD K, analyst calc) | — | -5,280.0 | -3,924.2 | -6,544.7 | -10,617 |
Equity raised incl option exercises, net (AUD K) | — | 5,879.0 | 2,765.0 | 22,563.4 | 1,215 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | — | -102.0 | -76.5 | -89.8 | -108.0 |
ROA on average assets (%) | — | — | -58.0 | -83.9 | -99.7 |
Current ratio (x) | — | 1.33 | 1.65 | 30.30 | 4.29 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Asset turnover (x) | — | — | 0.005 | 0.006 | 0.005 |
Revenue History
| Period | Revenue (AUD) | Net loss (AUD) | Liquidity at period end (AUD Mn) | Echos processed | Source |
|---|---|---|---|---|---|
H1 FY2025 (to 31 Dec 2024) | 101,409 | -6,215,645 | 5.35 | — | H1 FY2026 comparatives |
H1 FY2026 (to 31 Dec 2025) | 90,909 | -8,659,669 | 13.21 | — | H1 FY2026 report |
H2 FY2026 (analyst calc) | 737 | -9,906,086 | 8.71 | — | FY2026 less H1 |
Sep Q 2025 | — | — | 15.90 | +153% QoQ (integrated US customers) | Q1 FY2026 4C |
Dec Q 2025 | — | — | 13.21 | 3,992 | FY2026 AR |
Mar Q 2026 | — | — | 11.14 | 9,220 | FY2026 AR |
Jun Q 2026 | — | — | 8.71 | 10,200 | FY2026 AR |
Income Statement and Margin Analysis (%) by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Australia revenue (AUD K) | — | — | 44.5 | 101.4 | 91 |
United States revenue (AUD K) | — | — | 0 | 0 | 1 |
Total revenue (AUD K) | 904.1 | 107.3 | 44.5 | 101.4 | 91.6 |
Australia share of revenue (%) | — | — | 100 | 100 | 99 |
United States share of revenue (%) | — | — | 0 | 0 | 1 |
Region growth (%)
| Region growth (%) | FY2025 vs FY2024 | FY2026 vs FY2025 |
|---|---|---|
Australia | +128% | −10% |
United States | n/m (from zero) | n/m (A$1k) |
Share Price and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price FY high (AUD) | 0.19 | 0.23 | 0.21 | 0.36 | 1.62 |
Share price FY low (AUD) | 0.10 | 0.11 | 0.10 | 0.14 | 0.17 |
Shares on issue at year end (millions) | — | 472.3 | 537.7 | 645.2 | 660.9 |
Equity raised in year incl options (AUD Mn) | — | 5.9 | 2.8 | 22.6 | 1.2 |
Share Price & Returns
| Horizon | Performance | Basis |
|---|---|---|
Year to date 2026 | About +146% (A$0.26 to about A$0.64) | InvestSMART start-of-year price; latest reference price |
1 year | About +210% (about A$0.205 on 6 October 2025 to about A$0.64) | Analyst calculation |
From peak | About −65% (A$1.875 intraday high to about A$0.64–0.66) | Motley Fool, 23 September 2026 |
3 year | Not precisely verifiable. The FY2024 trading range of A$0.10–0.21 implies roughly 3–6x. | FY2026 remuneration report |
5 year | Not precisely verifiable. The A$0.05 placement price in March 2021 implies more than 10x. | Stockhead 2021 |
Valuation Snapshot
| Metric | Value | Derivation |
|---|---|---|
Market capitalisation | About A$474m | 740.6m shares × A$0.64 (matches the StockLight figure) |
Net cash | About A$95–105m | More than A$105m in July 2026, less estimated Q1 FY2027 burn. The September 2026 quarterly 4C was not yet available. |
Enterprise value | About A$370–380m | Market cap less net cash |
EV / FY2026 sales | About 4,000x | A$375m / A$0.092m |
P/E | Not meaningful (loss-making) | — |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
P/B (reported 30 June 2026 equity A$11.6m) | About 41x | Distorted by the timing of the raise |
P/B (pro forma equity about A$120m) | About 4.0x | Adds about A$108m net placement proceeds |
Peer multiples | Not computed. Comparable cardiac AI peers are mostly private. | — |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Date / notes |
|---|---|---|---|
Morgans | Speculative Buy | 1.85 | Held after the NSE (September 2026). Earlier A$1.75 after the placement. |
Ord Minnett (Tom Godfrey) | Positive | 1.80 | Raised 20% after the Pro Medicus HoA (June 2026). Ord Minnett was lead manager on the 2024 placement. |
Bell Potter | — | — | FY2026 EPS forecast −1.6c; FY2027 −1.9c (July 2026) |
Shaw and Partners | — | — | FY2026 EPS forecast −2.1c; FY2027 −1.4c |
Evolution Capital | Coverage noted | — | Referenced by Stockhead |
FNArena consensus | — | 1.683 | July 2026, before the NSE |
“—” = not publicly disclosed.
Catalyst / Monitorable Details
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
Disclosure of NSE reasons and the chosen pathway (appeal, Ombudsman or new 510(k)) | Q4 CY2026 | Sets the HF timeline |
Q1 FY2027 Appendix 4C (September quarter) | Late October 2026 | First post-raise burn, receipts and utilisation |
AGM | Q4 CY2026 | Remuneration report vote after the bonus decisions |
Pro Medicus binding reseller agreement and note funding | Q4 CY2026 to H1 CY2027 | Unlocks the A$10m tranche and the US channel |
Conversion of any of the three enterprise proposals | H1 CY2027 | First material contracted revenue |
CMS CY2027 hospital outpatient final rule (New Technology APC for software) | Around November 2026 | Reimbursement pathway |
JACC: Heart Failure publication of HF validation | Not dated | Evidence for regulators and payers |
Mayo cardio-oncology results | First half of CY2027 | Pipeline validation |
Director LTI tranche (a), FDA HF by 31 December 2026 | 31 December 2026 | Likely lapses; governance signal |
Use of placement proceeds for M&A | Ongoing | Capital allocation discipline |
Executive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education / age |
|---|---|---|---|---|
Dustin Haines | Chief Executive Officer (US-based) | Since 10 January 2025 | VP and GM, Gilead Sciences (Asia, Middle East, Turkey and Russia); Chief Commercial Officer, Next Science (ASX: NXS); over a decade at ViiV Healthcare and GSK across Japan, Europe and the US | Education and age not disclosed |
Matthew Dodds | Chief Financial Officer | Since 24 June 2026 | Senior roles at LivaNova PLC and Johnson & Johnson Medical Devices; over 20 years as a Wall Street medtech analyst | — |
Nick Lubbers | US President and General Manager | Appointed during FY2026 (date not disclosed) | Over 15 years in cardiovascular commercial roles at Boston Scientific, HeartFlow and Tempus | — |
Deon Strydom | Chief Commercial Officer (as quoted in November 2024) | — | — | Not disclosed; current status unconfirmed |
Jessamyn Lyons | Company Secretary | Since 22 October 2021 | Macquarie Bank, UBS (London), Patersons Securities | BCom (UWA); FGIA |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Background | Other listed boards (FY2026 AR) |
|---|---|---|---|---|
Andrew Grover | Executive Chair. Interim Managing Director until January 2025. | 24 May 2019 | Over 30 years as an entrepreneur and investor; businesses featured in BRW Fast 100 and Deloitte Fast 50; former CEO of a recruitment firm acquired by an ASX company | Chair of Nutritional Growth Solutions (NGS); director of Spacetalk (SPA) and Findi (FND) |
Steven Formica | Non-executive director | 2 July 2018 | Over 30 years in private businesses (manufacturing, construction, property, resources) | Multiple resources company chair and director roles (FY2025 AR: Ragnar Metals, Kaiser Reef, Albion Resources, Bindi Metals, Great Northern Minerals) |
Stephen Picton | Non-executive director | 20 October 2021 | BSc; MSc (London Business School); Sloan Fellow (1993); Chartered Engineer; senior roles at BT and AAPT; founded gotalk; relaunched LBNCo | Comms Group (CCG) |
Kenneth Nelson | Non-executive director (US-based) | 11 December 2024 | 25-year cardiac digital-health executive: BioTelemetry (Global VP Sales), iRhythm (VP Sales and Marketing), Bardy Diagnostics (CCO), Guidant/Boston Scientific, Biotronik; founder of Nelson Jennings Ventures | HeartBeam (NASDAQ: BEAT), Acarix (Nasdaq Stockholm), plus private boards |
Simon Tolhurst (former) | Non-executive director | 1 June 2023 to 11 December 2024 | Former HWL Ebsworth partner | Not applicable |
Directors' Remuneration
| KMP | Cash salary and fees (AUD) | Non-monetary (AUD) | Super (AUD) | Share-based payments (AUD) | Total FY2026 (AUD) | Total FY2025 (AUD) |
|---|---|---|---|---|---|---|
Andrew Grover (Executive Chair) | 345,700 | 0 | 28,800 | 1,453,749 | 1,828,249 | 949,266 |
Dustin Haines (CEO) | 589,506 | 55,045 | 0 | 1,013,933 | 1,658,484 | 741,698 |
Steven Formica (NED) | 66,000 | 0 | 7,920 | 804,404 | 878,324 | 394,537 |
Kenneth Nelson (NED) | 132,591 | 0 | 0 | 318,290 | 450,881 | 364,921 |
Stephen Picton (NED) | 54,054 | 0 | 6,486 | 0 | 60,540 | 61,277 |
Matthew Dodds (CFO, 24–30 June 2026) | 8,932 | 3,912 | 0 | 0 | 12,844 | 0 |
Total KMP | 1196783 | 58957 | 43206 | 3590376 | 4889322 | 2544699 |
Major Shareholders
| Holder | Shares | Approx. % of ~740.6m | Basis |
|---|---|---|---|
Steven Formica (and associates) | 33,016,667 | 4.5 | FY2026 AR, at 30 June 2026 |
A22 Pty Ltd (controlled by Mr Grover's spouse; Grover states no relevant interest) | 32,500,000 | 4.4 | FY2026 AR |
Stephen Picton (and associates) | 23,014,854 | 3.1 | FY2026 AR |
Stevsand Investment Pty Ltd | — | 2.95 (at November 2024, pre-dilution) | Biotech Daily, November 2024 |
Bellco Investment Pty Ltd (Northland super fund) | — | 2.59 (at November 2024, pre-dilution) | Biotech Daily, November 2024 |
Pro Medicus Limited | 0 ordinary shares; holder of convertible notes (A$10m initial, if issued) | Potential | FY2026 AR |
July 2026 placement institutions (unnamed domestic and international healthcare and technology funds) | 75862069 in aggregate | 10.2 in aggregate | ASX, 1 July 2026 |
Targets & Commitments
| Initiative | Date | Type | Status |
|---|---|---|---|
CEO hire (Haines) and US leadership build-out | January 2025 onward | Transformation | Complete; CFO added June 2026 |
OTCQB listing (ECHQF) | April 2025 | Capital markets / US investor access | Live |
BIDMC flagship integration and health-economics study | March 2025 onward | Commercial and evidence | Interim analysis shows statistically significant gains in utilisation and confidence |
Mayo Validate HF study, 510(k) submission | July–December 2025 | Regulatory | NSE received September 2026 |
Category III CPT application | June 2025 resubmission; September 2025 panel | Reimbursement | Rejected October 2025; engagement continues |
10 new patent applications and 4 trademarks | March quarter 2026 | Intellectual property | Filed |
Expanded Mayo agreement (HF resale, 6-year term) | March 2026 | Distribution | Contingent on FDA clearance |
Mount Sinai deployment | April 2026 | Commercial | Live |
EchoSolv VIEW, SHADOW and third installation pathway | June quarter 2026 | Go-to-market | Live; three enterprise proposals |
Mayo cardio-oncology research | June 2026 | Pipeline | Results expected first half of CY2027 |
Pro Medicus HoA and convertible note agreement | June and August 2026 | Strategic partnership and funding | Notes documented; reseller agreement pending |
Advara HeartCare data licence | June/July 2026 | Data | Executed |
A$110m placement | July 2026 | Capital | Completed |
HF regulatory remediation (appeal, Ombudsman or new 510(k)) | September 2026 onward | Regulatory | In progress |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Product | Ownership | Revenue (relevant) | Relative positioning vs Echo IQ |
|---|---|---|---|---|---|
Ultromics (UK) | Heart failure (HFpEF), cardiac amyloidosis | EchoGo HF, EchoGo Amyloidosis (image-based echo AI; FDA-cleared HF product) | Private, venture-backed | — | Most direct HF competitor. Image-based rather than measurement-based. Already holds HF clearance, a head start Echo IQ lost in September 2026. |
Us2.ai (Singapore) | Echo automation and measurements; HF | Automated echo analysis | Private | — | Automates the measurements Echo IQ consumes. Could move into disease scoring. |
iCardio.ai (US) | Echo AI | Echo interpretation AI | Private | — | Emerging competitor |
GE HealthCare (incl. Caption Health) | Echo hardware with embedded AI | Vivid ultrasound with AI tools | Public (NASDAQ: GEHC) | Multi-billion company-wide; echo AI not segmented | Can bundle AI natively at acquisition |
Philips (incl. DiA Imaging Analysis) | Echo hardware and AI | EPIQ/Affiniti with AI quantification | Public (Euronext: PHIA) | Multi-billion; not segmented | Bundling threat |
Siemens Healthineers | Echo hardware and AI | Acuson with AI | Public | Multi-billion; not segmented | Bundling threat |
Anumana (US) | Heart-failure detection (low EF via ECG) | ECG-AI | Private | — | Different modality, same clinical goal of earlier HF detection |
Eko Health (US) | Valve disease and low EF screening | AI stethoscope | Private | — | Upstream screening alternative (murmur/AS detection) |
Viz.ai (US) | Cardiovascular care coordination (e.g. HCM) | Viz HCM and care-pathway AI | Private | — | Competes for health-system "cardio AI" budgets and workflow |
Tempus (US) | Cardiology AI (ECG-based) | Tempus ECG algorithms | Public (NASDAQ: TEM) | Not segmented | Competes for cardiology data-AI mindshare |
HeartFlow (US) | Cardiac AI (CT-FFR) | FFRct / Plaque Analysis | Public | — | Adjacent. Benchmark for the reimbursement-led AI scaling Echo IQ aims to copy (US President Lubbers is a HeartFlow alumnus). |
“—” = not publicly disclosed.
Competitor Detail
| Metric | Echo IQ (FY2026) |
|---|---|
Revenue | A$0.09m |
Revenue growth | −9.6% |
Net margin | −20,258% |
FDA-cleared echo AI indications | 1 (AS) |
Recent Developments
--



